BMC Geriatrics, 2005 Background Rivastigmine, a butyl- and acetylcholinesterase inhibitor, is approved for symptomatic treatment of Alzheimer's disease (AD). Data supporting the safety and efficacy of second-generation cholinesterase inhibitors, such as rivastigmine, are ...
Lilly Mary L, Farlow Martin R
doaj +1 more source
New N,N-dimethylcarbamate inhibitors of acetylcholinesterase: design synthesis and biological evaluation [PDF]
, 2016 A series of N,N-dimethylcarbamates containing a N,N-dibenzylamino moiety was synthesized and tested to evaluate their ability to inhibit Acetylcholinesterase (AChE).
Chiarotto, Isabella +9 more
core +1 more source
Atypical Presentation of Acetylcholinesterase Inhibitor-Induced Diarrhea in Older Adults with Cognitive Decline: An Aspect not to be Underestimated [PDF]
Annals of Geriatric Medicine and Research, 2023 The rivastigmine patch is the only existing transdermal delivery system used for the treatment of Alzheimer disease. Among the most common adverse events derived from its use are gastrointestinal events, particularly diarrhea.
Raffaele Pagliuca +4 more
doaj +1 more source
Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada. [PDF]
, 2015 This survey analyzes two national pharmacovigilance databases in order to determine the major adverse reactions observed with the use of cholinesterase inhibitors in dementia.
Abagyan, Ruben +4 more
core +3 more sources
Adherence and Tolerability of Alzheimer's Disease Medications: A Pragmatic Randomized Trial [PDF]
, 2017 BACKGROUND/OBJECTIVES: Post-marketing comparative trials describe medication use patterns in diverse, real-world populations. Our objective was to determine if differences in rates of adherence and tolerability exist among new users to ...
Boustani, Malaz A. +8 more
core +1 more source
Rivastigmine to treat anticholinergic toxicity following drug overdose – case series
Toxicology CommunicationsIntroduction Overdose involving anticholinergic agents frequently cause delirium and agitation, for which the antidote of choice is physostigmine. Due to unpredictable physostigmine availability, rivastigmine has been proposed as an alternative therapy ...
Joseph E. Lambson +2 more
doaj +1 more source
Current Research in Pharmacology and Drug Discovery, 2022 Alzheimer's Disease (AD) is characterized as a progressive neurodegenerative disease most commonly associated with memory deficits and cognitive decline.
Yasir Hasan Siddique +3 more
doaj +1 more source
A 24-Week, Open-Label Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of 13.3 mg/24 h Rivastigmine Patch in Patients With Severe Alzheimer Disease [PDF]
, 2015 The long-term safety, tolerability, and efficacy of high-dose 13.3 mg/24 h rivastigmine patch in severe Alzheimer disease was evaluated in a 24-week, open-label extension to the double-blind ACTION study.
Farlow, Martin R. +4 more
core +1 more source
Антибиотики и Химиотерапия, 2023 The basis for conducting bioequivalence studies is the determination of the bioavailability of the active substance of the drug at its place of action by establishing the concentration of the drug in biological fluids using sensitive analytical techniques.
M. S. Dolov +3 more
doaj +1 more source
Effects of non-pharmacological or pharmacological interventions on cognition and brain plasticity of aging individuals. [PDF]
, 2014 Brain aging and aging-related neurodegenerative disorders are major health challenges faced by modern societies. Brain aging is associated with cognitive and functional decline and represents the favourable background for the onset and development of ...
Cesinaro, Stefano +4 more
core +2 more sources